Yeah, I believe you are correct. Lot of off-label in cancer, with NCCN recommendations. There is already some off-label with maraviroc as I posted about earlier.

I wonder how that fix that with the licensing deals? If they have one for HIV and a separate one for cancer. I suspect the cancer partner wouldn't like off-label sales going to the HIV partner. And it could become a considerable amount with more great cancer results in human trials.